Update: MRI in Multiple sclerosis
|
|
- Stuart McCarthy
- 8 years ago
- Views:
Transcription
1 Nyt indenfor MS ved MR Update: MRI in Multiple sclerosis Hartwig Roman Siebner Danish Research Centre for Magnetic Resonance (DRCMR) Copenhagen University Hospital Hvidovre Dansk Radiologisk Selskabs 10. årsmøde Januar 30 th 2015
2 Use of MRI in Multiple Sclerosis Clinically Isolated Syndrome (CIS): Diagnosis, prognosis (early conversion) Multiple Sclerosis: Monitoring disease progression Inflammation: disease activity (frequency & severity of relapses), monitoring (PML), prognosis, predicting treatment response Neurodegeneration: prognosis, predicting treatment response, assessing neuroprotective effect Clinical trials (Reader centre) Stratifying study populations Primary endpoint (phase II clinical trials) Secondary endpoint (phase III clinical trials)
3 Cortical lesion morphology in MS Type I (leukocortical) spanning the grey matter white matter (GM/WM) boundary Type II (intracortical) does not involve the pial surface or GM/WM boundary Type III/IV (subpial) extends from the pial surface to various depths of the cortex without involving the WM
4 Double Inversion Recovery (DIR) MRI Two non-selective inversion pulses applied before a Turbo Spin Echo (TSE) sequence to suppress the signal from two tissues with different longitudinal relaxation times T(1) simultaneously. For brain imaging in MS, DIR is used to selectively image the gray matter (GM) by nulling the signal from white matter (WM) and cerebrospinal fluid (CSF). The main limitation of the technique remains the intrinsic low SNR due to the specific preparation of the longitudinal magnetization. 7T!!!
5 Changes in Brain Volume in Multiple Sclerosis BRAIN VOLUME INCREASE Inflammation Remyelination Gliosis Oedema Hyperhydration BRAIN VOLUME LOSS Axonal loss Demyelination Gliosis Resolution of oedema Hyperhydration Resolution of inflammation (Pseudoatrophy)
6 Use of MRI to assess tissue loss in Multiple Sclerosis Loss of brain tissue (axons / myelin / glia) => Contributes to fixed disability MR-methods used to assess disease-related atrophy: Sensitive: detection of minimal tissue loss Reproducible: Minimal variation over repeated measurements Accurate: Reliable assignment of a voxel to the correct tissue class (white and grey matter, lesion), partial volume effects Automated: Efficient, streamlined, standardized procedure Robust towards variations in image quality
7 Brain atrophy volume loss Brain atrophy is inferred from brain volume shrinkage, which is most readily measured from sequential T1-weighted scans before gadolinium administration. Segmentation-based (Voxel-based morphometry VBM) and/or registration-based analysis (SIENA) techniques are used to determine brain volume changes over time. Temporary brain volume loss due to water shifts, termed pseudoatrophy, can be observed after alcohol intake, and use of steroids and other anti-inflammatory drugs.
8 Progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab MRI: most sensitive detection and monitoring tool in the detection of PML lesions - before clinical symptoms occur and JC-Virus DNA becomes detectable in the CSF. MRI protocol for PML screening: FLAIR (highest overall sensitivity) and DWI (active and acute PML lesions). MRI phenotype of natalizumab-associated PML is rather heterogeneous and fluctuating (showing signs of inflammation and cortical GM involvement. Wattjes and Barkhof Curr Opin Neurol 2014
9 Diagnosis and monitoring of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab MRI is the most sensitive diagnostic tool in the detection of PML lesions - before clinical symptoms occur and JCV DNA becomes detectable in the CSF. In MRI protocol for PML screening should include FLAIR (highest overall sensitivity) and DWI (depiction of active and acute PML lesions). MRI appearance of natalizumab-associated PML is rather heterogeneous and fluctuating, including signs of inflammation and showing cortical GM involvement. Wattjes and Barkhof Curr Opin Neurol 2014
10 MRI biomarkers in clinical trials: the focus is on acute inflammatory markers Clinical activity MRI activity Relapse free Disability progression free Gd+ lesion free T2 lesion free Challenge: to close the clinical-radiological gap Natalizumab treatment: Risk of progressive multifocal leukoencephalopathy (PML) caused by JC virus (JCV) activation especially in Anti-JCV pos. patients Freedom from disease activity Brain and spinal cord atrophy NAWM & NAGM microstructure (DTI,MTR,MRS) NAWM - Normal appearing white matter NAGM - Normal appearing grey matter
Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI
Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI Background information Progressive multifocal leukoencephalopathy (PML) PML is a demyelinating disease that attacks the
More informationMultiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
More informationAdvances in the Use of MRI in the Management of MS. The Role of MRI in MS Management. Jack H. Simon Portland, Oregon
Advances in the Use of MRI in the Management of MS The Role of MRI in MS Management Jack H. Simon Portland, Oregon Disclosures Dr. Simon has nothing to disclose. This continuing education activity is managed
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationMultiple Sclerosis. Matt Hulvey BL A - 615
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationNeuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of MRI in Diagnosing and Monitoring MS Jack H. Simon, Portland, OR
Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of MRI in Diagnosing and Monitoring MS Jack H. Simon, Portland, OR What MRI Taught Us about Neurodegeneration and MS Matilde Inglese, NewYork MRI
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationMRI in Differential Diagnosis
MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationAccuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationNatalizumab and the Risk of PML
Natalizumab and the Risk of PML Gloria von Geldern, MD Multiple Sclerosis Center Assistant Professor of Neurology University of Washington May 13, 2015 Conflict of Interest Dr. von Geldern has nothing
More informationIF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
More informationClinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationUse of imaging in multiple sclerosis
CHAPTER 3 Use of imaging in multiple sclerosis M. Filippi, 1 M. A. Rocca, 1 D. L. Arnold,2 R. Bakshi,3 F. B ar khof, 4 5 N. De Stefano, F. Fazekas,6 E. Frohman,7 D. H. Mil le r, 8 9 J. S. Wolinsky 1 Institute
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationThe Many Faces of MS
The Many Faces of MS Patricia A. Modica, OD, FAAO SUNY College of Optometry Kelly Malloy, OD, FAAO Pennsylvania College of Optometry at Salus University Multiple Sclerosis (MS) Most common acquired disease
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationOur concept of multiple sclerosis (MS) as
MEASURING AND ASSESSING NEURODEGENERATION AND NEUROPROTECTION: THE ROLE OF MRI * Nancy Richert, MD, PhD ABSTRACT Multiple sclerosis is a complex disease involving inflammatory and neurodegenerative processes.
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationMRI in drug development: Lessons from MS
MRI in drug development: Lessons from MS Douglas L. Arnold MD McConnel Brain Imaging Center, MNI, McGill NeuroRx Research Inc Drug development Pre-clinical Phase I Phase II Phase III Phase IV Candidate
More informationGE Medical Systems Training in Partnership. Module 8: IQ: Acquisition Time
Module 8: IQ: Acquisition Time IQ : Acquisition Time Objectives...Describe types of data acquisition modes....compute acquisition times for 2D and 3D scans. 2D Acquisitions The 2D mode acquires and reconstructs
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationSensitive and reproducible clinical rating
CLINICAL AND MRI MARKERS OF MS DISEASE PROGRESSION * Richard A. Rudick, MD ABSTRACT Sensitive and reproducible measures of multiple sclerosis (MS) severity and progression are important in the treatment
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationDisease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationMagnetic Resonance Imaging
Magnetic Resonance Imaging What are the uses of MRI? To begin, not only are there a variety of scanning methodologies available, but there are also a variety of MRI methodologies available which provide
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationNatalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY
Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin
More informationProgress in the field: therapeutic improvements for all patients?
Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination
More informationNew Approaches to Neuroimaging of Progressive Multifocal Leukoencephalopathy. Alexandra Binnie, HMS III Gillian Lieberman, M.D.
New Approaches to Neuroimaging of Progressive Multifocal Leukoencephalopathy Alexandra Binnie, HMS III Gillian Lieberman, M.D. What is Progressive Multifocal Leukoencephalopathy (PML)? A demyelinating
More informationReversibility of Acute Demyelinating Lesions in relapsingremitting
Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs
More informationWhat is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
More informationCBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area
April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the
More informationMRI for Paediatric Surgeons
MRI for Paediatric Surgeons Starship David Perry Paediatric Radiologist Starship Children s Hospital CHILDREN S HEALTH What determines the brightness of a pixel in MRI? i.e. What determines the strength
More informationNew research in primary and secondary progressive multiple sclerosis. Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital
New research in primary and secondary progressive multiple sclerosis Huntingdon MS Society Annual Meeting Sat 22nd March 2014 Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital 1 Overview
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationThe following MS experts were involved in the development of this Position Statement:
Position Statement for TYSABRI (natalizumab) and STRATIFY JCV TM in Multiple Sclerosis Rationale for this Position Statement This Position Statement was developed by ten Australian neurologists who specialise
More informationA Letter From the MS Coalition
0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding
More informationClinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
More informationUnderstanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
More informationMRI SEQUENCES. 1 Gradient Echo Sequence
5 An MRI sequence is an ordered combination of RF and gradient pulses designed to acquire the data to form the image. In this chapter I will describe the basic gradient echo, spin echo and inversion recovery
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationTreatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationThe Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
More informationThe role of MRI in modern management of and treatment decisions in MS
The role of MRI in modern management of and treatment decisions in MS franz.fazekas@medunigraz.at Vienna, September 25, 2013 Department of Neurology, http://neurologie.uniklinikumgraz.at Disclosures 8
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationQuantitative Assessment of MRI Features in Patients with Relapsing-Remitting Multiple Sclerosis
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, August 2014. Vol. 11(2), 863-868 Quantitative Assessment of MRI Features in Patients with Relapsing-Remitting Multiple Sclerosis Babak Shekarchi 1, Samaneh Fartook
More informationNeuroimaging module I: Modern neuroimaging methods of investigation of the human brain in health and disease
1 Neuroimaging module I: Modern neuroimaging methods of investigation of the human brain in health and disease The following contains a summary of the content of the neuroimaging module I on the postgraduate
More information2. MATERIALS AND METHODS
Difficulties of T1 brain MRI segmentation techniques M S. Atkins *a, K. Siu a, B. Law a, J. Orchard a, W. Rosenbaum a a School of Computing Science, Simon Fraser University ABSTRACT This paper looks at
More informationTable 11: Pros and Cons of 1.5 T MRI vs. 3.0 T MRI; Safety and Technical Issues, and Clinical Applications
Safety Issue 3.0 T MRI Pro 3.0 T MRI Con Immediate fringe field surrounding magnet A ferromagnetic object inadvertently brought into the scan room will experience a sharp increase in attraction toward
More informationGE Medical Systems Training in Partnership. Module 12: Spin Echo
Module : Spin Echo Spin Echo Objectives Review the SE PSD. Review the concepts of T, T, and T*. Spin Echo PSD RF Gz Gy 90 80 Gx Spin Echo - SE Spin echo is a standard pulse sequence on Signa MRi/LX and
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 16 November 2006 Doc. Ref. CPMP/EWP/561/98 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE
More informationTreatment Optimization in MS: When to Start, When to Shift, when to Stop
Treatment Optimization in MS: When to Start, When to Shift, when to Stop Mark S. Freedman MSc MD FAAN FANA FRCPC Director, Multiple Sclerosis Research Unit University of Ottawa Sr. Scientist, Ottawa Hospital
More informationProjects at the Danish Research Centre for Magnetic Resonance
Projects at the Danish Research Centre for Magnetic Resonance Five projects involving Magnetic Resonance Imaging (MRI) Hvidovre Hospital Example: [1-13C]Pyruvate signal enhanced by ~50,000x! Magnetic Resonance
More informationOutcome and survival of asymptomatic PML in natalizumab-treated MS patients
RESEARCH ARTICLE Outcome and survival of asymptomatic PML in natalizumab-treated MS patients Tuan Dong-Si 1,a, Sandra Richman 1, Mike P. Wattjes 2, Made Wenten 1, Sarah Gheuens 1, Jeffrey Philip 3, Shoibal
More informationHomework 5: Differential Diagnosis of Multiple Sclerosis
Homework 5: Differential Diagnosis of Multiple Sclerosis Due Wednesday, 3/3/99 1.0 Background Multiple Sclerosis affects approximately 350 K Americans and is the leading nontraumatic source of neurologic
More informationMULTIPLE SCLEROSIS Update. Disclosures. Multiple Sclerosis. I do not have any disclosures. E. Torage Shivapour, M.D.
MULTIPLE SCLEROSIS Update E. Torage Shivapour, M.D. Clinical Professor Department of Neurology University of Iowa Hospitals & Clinics Disclosures I do not have any disclosures. Multiple Sclerosis Most
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationMolecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD)
Brain Research Center Medical University of Vienna Molecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD) IMMUNOLOGY OF MULTIPLE SCLEROSIS Noseworthy et al 2000 NEJM Immunomodulatory Treatment
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationfingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK
fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationMultiple sclerosis (MS) is the most frequent chronic inflammatory
ORIGINAL RESEARCH M.P. Wattjes G.G. Lutterbey J. Gieseke F. Träber L. Klotz S. Schmidt H.H. Schild Double Inversion Recovery Brain Imaging at 3T: Diagnostic Value in the Detection of Multiple Sclerosis
More information43. MULTIPLE SCLEROSIS
Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System, as agreed by the Interterritorial Board 43. MULTIPLE
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 September 2005 Doc. Ref. EMEA/CHMP/EWP/561/98 Rev 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
More informationTITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central
More informationAcute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD
Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD Acute demyelinating optic neuritis associated with multiple sclerosis (MS) is
More information2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
More informationMS Treatments Gilenya
1 MSology Essentials Series Gilenya (fingolimod) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Trudy Campbell Dalhousie MS Research Unit, Capital Health, Halifax,
More informationNew Developments in the Treatment and Management of Multiple Sclerosis
New Developments in the Treatment and Management of Multiple Sclerosis Myla D. Goldman, MD, MS For a CME/CEU version of this article, please go to www.namcp.org/cmeonline.htm, and then click the activity
More informationPrimary Progressive MS: Diagnosis, Clinical Course, and Long-Term Management
Primary Progressive MS: Diagnosis, Clinical Course, and Long-Term Management Consultant: Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, Teva Research: Actelion,
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationMS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
More informationBest practices for using MS disease modifying therapies
Best practices for using MS disease modifying therapies CMSC Annual Meeting 2015 COREY C FORD, MD, PHD MS SPECIALTY CLINIC UNIVERSITY OF NEW MEXICO HSC MAY 30, 2015 Objectives Use best practices to select
More information09/05/2014. Painting pictures of the brain with numbers. Overview
Painting pictures of the brain with numbers Neurology for Insurers Dr Ian Cox & Adele Groyer (Gen Re) Overview Critical Illness Product Background Why should we be interested in neurology? Consult our
More informationMultiple Sclerosis (Dr. Merchut) 1. Pathophysiology
Multiple Sclerosis (Dr. Merchut) 1. Pathophysiology Multiple sclerosis (MS) is an acquired disorder with immune-mediated destruction of normal central nervous system (CNS) myelin with secondary loss of
More informationVoting for your top research questions Survey
MS Priority Setting Partnership Voting for your top research questions Survey Prioritising important research questions for multiple sclerosis a partnership between people affected by MS and healthcare
More informationAUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationAdvanced MRI methods in diagnostics of spinal cord pathology
Advanced MRI methods in diagnostics of spinal cord pathology Stanisław Kwieciński Department of Magnetic Resonance MR IMAGING LAB MRI /MRS IN BIOMEDICAL RESEARCH ON HUMANS AND ANIMAL MODELS IN VIVO Equipment:
More informationSummary chapter 2 chapter 2
Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological
More informationCollaborative Network Award Planning Grants Project Summaries
Collaborative Network Award Planning Grants Project Summaries PRIORITY AREA: Projects that will drive development of one or more pre-clinical drug candidates through identification and validation of molecular
More informationDisease modifying drug therapy
Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationDisclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.
Disclosure Statement Multiple Sclerosis: Current Trends in Treatment Member of Speaker s Bureau Biogen Idec Will discuss non FDA approved therapies Christine St Laurent MSN, RN, MSCN 19 th Annual Mud Season
More information